Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2006-10-17
2006-10-17
Kerr, Kathleen M. (Department: 1656)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C435S069100, C435S069600, C930S100000, C530S380000
Reexamination Certificate
active
07122634
ABSTRACT:
Specific amino acid loci of human factor VIII interact with inhibitory antibodies of hemophilia patients who have developed such antibodies after being treated with factor VIII. Modified factor VIII is disclosed in which the amino acid sequence is changed by a substitution at one or more of the specific loci. The modified factor VIII is not inhibited by inhibitory antibodies against the A2 or C2 domain epitopes. The modified factor VIII is useful for hemophiliacs, either to avoid or prevent the action of inhibitory antibodies.
REFERENCES:
patent: 4757006 (1988-07-01), Toole
patent: 4868112 (1989-09-01), Toole
patent: 5364771 (1994-11-01), Lollar
patent: 5563045 (1996-10-01), Pittman et al.
patent: 5663060 (1997-09-01), Lollar et al.
patent: 6770744 (2004-08-01), Lollar
patent: 2004/0123997 (2004-07-01), Drane et al.
patent: 2004/0249134 (2004-12-01), Lollar
patent: 0 182 448 (1986-05-01), None
patent: 0 306 968 (1988-09-01), None
patent: WO 91/07438 (1990-11-01), None
patent: WO 93/20093 (1993-10-01), None
patent: WO 94/11503 (1994-05-01), None
patent: WO 95/24427 (1995-09-01), None
patent: WO 97/03191 (1997-01-01), None
patent: WO 97/03193 (1997-01-01), None
patent: WO 99/46274 (1999-09-01), None
Arruda et al. Eleven Novel Mutations in the Factor VIII Gene from Brazilian Hemophilia Patients. (Oct. 1995) Blood, vol. 86, No. 8, pp. 3015-3020.
Cunningham, B.C. et al. “High-Resolution Epitope Mapping of HGH-Receptor Interactions by Alanine-Scanning Mutagenesis”; (1989)Science, US, American Association for the Advancement of Science244(4908):1081-1085.
Lubin et al. “Analysis of the human factor VIII A2 inhibitor epitope by alanine scanning mutagenesis”; (1997)J. Biol. Chem., 272(48):30191-30195.
Shima, M. et al. “A Factor VIII Neutralizing Monoclonal Antibody and a Human Inhibitor Alloantibody Recognizing Epitopes in the C2 Domain Inhibit Factor VIII Binding to Von Willebrand Factor and to Phosphatidylserine”; (1993)Thrombosis and Haemostasis, Stuttgart, DE 69(3):240-246.
Barrow, R.T. et al. (2001) “Amino Acid Residues R2215, R2220, and F2196 Contribute to the Antigenicity of the Human Factor VIII C2 Domain Toward Inhibitory Antibodies”;Blood98(11):531a. Abstract only.
Gilbert G.E. et al. (2000) “Four Hydrophobic Amino Acids of the Factor VIII Domain Contribute to the Membrane-Binding Motif”;Blood96(11):633. Abstract only.
Nogami, K. et al. (1999) “Identification of a Factor VIII Peptide, Residues 2315-2330, Which Neutralizes Human Factor VIII C2 Inhibitor Alloantibodies: Requirement of CYS2326 and GLU2327 for Maximum Effect”;Brit. J. of Haem.107(1):196-203.
Church, et al. “Coagulation factors V and VIII and ceruloplasmin constitute a family of structurally related proteins”; (1984)Proc. Natl. Acad. Sci. USA81:6934.
Dominguez, O. et al. “Gene walking by unpredictably primed PCR”; (1994)Nucleic Acids Res.22:3247-3248.
Eaton, D.L. et al. “Construction and Characterization of an Active Factor VIII Variant Lacking the Central One-Third of the Molecule” (1986)Biochemistry25(26):8343-8347.
Fulcher, C.A. et al. “Localization of human factor FVIII inhibitor epitopes to two polypeptide fragments”; (1985)Proc. Natl. Acad. Sci. USA82:7728-7732.
Healy, J.F. et al. “The cDNA and Derived Amino Acid Sequence of Porcine Factor VIII”; (1996)Blood88:4209-4214.
Gitcher, J. et al. Characterization of the human factor VIII gene; (1984)Nature312:326-330.
Healey, J.F., Lubin, I.M., Lollar, P., EMBL/GENBANK/DDBJ databanks, Aug. 1996.
Lubin, et al. “Elimination of a Major Inhibitor Epitope in Factor VIII”; (1994)J. Biol. Chem.269:8639-8641.
Nakai, H. et al. “ Properties of Affinity Purified Anti-factor VIII Antibodies from Patients with Factor VIII Inhibitors”; (1994)Blood84:224a.
Ochman, H. et al. “Inverse Polymerase Chain Reaction”; (1990)Biotech.N.Y. 8:759-760.
Parker, J.D. et al. “Targeted gene-walking polymerase chain reaction”; (1991)Nucleic Acids. Res.19:3055-3060.
Parker, J.D. et al. “The Oligomer Extension ‘Hot Blot’; A Rapid Alternative to Southern Blots for Analyzing Polymerase Chain Reaction Products”; (1991)Biotechniques10:94-101.
Sarkar, G. et al. “Restriction-site PCR: A Direct Method of Unknown Sequence Retrieval Adjacent to a Known Locus by Using Universal Primers”; (1993)PCR Meth. Appl.2:318-322.
Scandella, D. et al. “Epitope mapping of human factor VIII inhibitor antibodies by deletion analysis of factor VIII fragments expressed inEscherichia coli”; (1988)Proc. Natl. Acad. Sci. USA85:6152-6156.
Scandella, D. et al. “Localization of epitopes for human factor VIII inhibitor antibodies by immunoblotting and antibody neutralization” (1989)Blood74:1618-1626.
Scandella, D. et al. “Some Factor VIII Inhibitor Antibodies Recognize a Common Epitope Corresponding to C2 Domain Amino Acids 2248 Through 2312, Which Overlap a Phospholipid-Binding Site”; (1995)Blood86:1811-1819.
Scandella, D. et al. “A recombinant factor VIII A2 domain polypeptide quantitatively neutralizes human inhibitor antibodies that bind to A2”; (1993)Blood82(6):1767-1775.
Siebert, P.D. et al. “An improved PCR method for walking in unclosed genomic DNA”; (1995)Nucleic Acids Res.23:1087-1088.
Toole, et al. “Molecular cloning of a cDNA encoding human antihaemophilic factor”; (1984)Nature312:342-347.
Toole, et al. “A large region (≈ 95 kDa) of human factor VIII is dispensable forin vitroprocoagulant activity”; (1986)Proc. Natl. Acad. Sci. USA83:5939-5942.
Verma et al. Gene Therapy—promises, problems and prospects, (Sep. 1997),Nature389:239-242.
Data Base Swiss-Prot Fa8—PIG, Oct. 1, 1989 “Coagulation Factor VIII Precursor”; Database Accession No. P12263.
Supplementary European Search Report, Sep. 21, 2004.
Pittman, DD et al. (1993) “Biochemical Immunological andin vivoFunctional Characterization of B-Domain Deleted Factor VIII”;Blood81(11):2925-2935.
Lind et al. (1995) “Novel forms of B-domain-deleted recombinant factor VIII molecules. Construction and biochemical characterization”;Eur. J. Biochem232(1):19-27.
Bihoreau, N et al. (1991) “Structural and Functional Characterization of Factor VIII-ΛII, a new recombinant Factor VIII lacking most of the B-domain”;Biochem. J.277-23-31.
Muelien, P (1988) “A new recombinant procoagulant protein derived from the cDNA encoding Human Factor VIII”;Protein Engineering2(4):301-306.
Sarver, N et al. (1987) “Stable Expression of Recombinant Factor VIII Molecules Using a Bovine Papillomavirus Vector”;DNA6(6):553-564.
Emory University
Greenlee Winner and Sullivan PC
Kerr Kathleen M.
Schnizer Holly
LandOfFree
Modified factor VIII does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Modified factor VIII, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modified factor VIII will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3680465